Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-755 with minimal to no plasma exchange in immune-mediated TTP
2023-507787-39-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of Apadamtase alfa in thrombotic thrombocytopenic purpura (TTP), sponsored by Takeda. Primary endpoint: Incidence of AEs, SAEs, and AESIs after receiving any dose of investigational product. Started Sep 2024; status: completed.
02
Drugs
Apadamtase alfa
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2023-507787-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507787-39-00.